FDA Approves First Drug to Help Infantile-Onset Niemann-Pick Disease Type C Patients Live Longer
The U.S. Food and Drug Administration has approved Lembaz (adrabetadex) injection as the first treatment demonstrated to help individuals with a severe form of Niemann-Pick disease type C live longer. The drug is indicated to reduce the risk of death in adult and pediatric patients weighing at least 7 kg whose neurological symptoms began before the age of six, referred to as infantile-onset NPC.
Administered as an intrathecal injection into the spinal canal every two weeks by a trained healthcare provider, Lembaz showed a 55 percent reduction in the risk of death compared to a matched external control group in clinical evaluations. Common side effects include hearing issues, balance and coordination problems, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough. The product includes a boxed warning for hearing impairment, including permanent hearing loss.
Key points
- Lembaz is the first FDA-approved therapy shown to reduce the risk of death in infantile-onset Niemann-Pick disease type C patients.
- It is approved for adult and pediatric patients weighing at least 7 kg with neurological symptoms starting before age 6.
- The drug is administered via intrathecal injection into the spinal canal every two weeks.
- Lembaz carries a boxed warning for hearing impairment and permanent hearing loss, requiring baseline and regular hearing evaluations.
What it means for you
Clinicians and pharmacists should note the approval of Lembaz for infantile-onset Niemann-Pick disease type C and its associated boxed warning for permanent hearing loss, which necessitates regular hearing monitoring. Because this is an FDA approval announcement, clinicians in Pakistan should check with DRAP regarding local registration and availability before seeking to procure or prescribe the product.
FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.
